Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Exp Pharmacol Physiol ; 46(2): 173-182, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30347478

RESUMO

We have previously demonstrated that the activation of the spleen tyrosine kinase (Syk)/inhibitory-κB (IκB)-α/nuclear factor-κB (NF-κB) p65 signalling pathway contributes to hypotension and inflammatory response in a rat models of zymosan (ZYM)-induced non-septic shock. The purpose of this study was to further examine the possible mechanism underlying the effect of inhibition of Syk by BAY61-3606 via NF-κB activity at the level of nuclear translocation regarding the production of vasodilator and proinflammatory mediators in lipopolysaccharide (LPS) (septic)- and ZYM (non-septic)-induced shock. Administration of LPS (10 mg/kg, ip) or ZYM (500 mg/kg, ip) to male Wistar rats decreased mean arterial pressure and increased heart rate that was associated with an increase in the activities of cyclooxygenase and nitric oxide synthase, tumour necrosis factor-α, and interleukin-8 levels, and NF-κB activation and nuclear translocation in sera and/or cardiovascular and renal tissues. BAY61-3606 (3 mg/kg, ip), the selective Syk inhibitor, given 1 hour after LPS- or ZYM injection reversed all the above-mentioned effects. These results suggest that Syk contributes to the LPS- or ZYM-induced hypotension and inflammation associated with transactivation of NF-κB in septic and non-septic shock.


Assuntos
Hipotensão/tratamento farmacológico , Lipopolissacarídeos/farmacologia , NF-kappa B/metabolismo , Niacinamida/análogos & derivados , Pirimidinas/farmacologia , Choque Séptico/tratamento farmacológico , Quinase Syk/antagonistas & inibidores , Zimosan/farmacologia , Animais , Ciclo-Oxigenase 2/metabolismo , Modelos Animais de Doenças , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Hipotensão/metabolismo , Hipotensão/patologia , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Inflamação/patologia , Interleucina-8/metabolismo , Masculino , Inibidor de NF-kappaB alfa/metabolismo , Niacinamida/farmacologia , Niacinamida/uso terapêutico , Óxido Nítrico Sintase Tipo II/metabolismo , Inibidores de Proteínas Quinases/farmacologia , Inibidores de Proteínas Quinases/uso terapêutico , Pirimidinas/uso terapêutico , Ratos , Ratos Wistar , Fator de Necrose Tumoral alfa/metabolismo
2.
Reprod Toxicol ; 79: 79-83, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29908288

RESUMO

OBJECTIVE: To investigate the pregnancy outcomes of women who were exposed to betahistine during their pregnancies. METHODS: We identified and evaluated the outcomes of 27 pregnant women who were referred to Terafar (Teratology Information Service, Izmir, Turkey) for a teratological risk assessment. RESULTS: Of 24 pregnancies with known outcomes, 21 resulted in live births (including two pairs of twins) whereas two ended with miscarriage and three with elective terminations. Among the 20 live births for whom the malformation details were available, there were 17 normal outcomes, one major and two minor congenital malformations. CONCLUSIONS: Despite a number of limitations, this case series may be of value regarding counseling pregnant women with inadvertent betahistine exposure. Further epidemiological studies with larger sample sizes and control groups are necessary to draw more definite conclusions.


Assuntos
Anormalidades Induzidas por Medicamentos/epidemiologia , beta-Histina/efeitos adversos , Agonistas dos Receptores Histamínicos/efeitos adversos , Resultado da Gravidez/epidemiologia , Adulto , Feminino , Humanos , Masculino , Troca Materno-Fetal , Pessoa de Meia-Idade , Gravidez , Turquia/epidemiologia , Adulto Jovem
3.
Eur J Pharmacol ; 802: 7-19, 2017 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-28228357

RESUMO

Mammalian target of rapamycin (mTOR), a serine/threonine kinase plays an important role in various pathophysiological processes including cancer, metabolic diseases, and inflammation. Although mTOR participates in Toll-like receptor 4 signalling in different cell types, the role of this enzyme in sepsis pathogenesis and its effects on hypotension and inflammation in endotoxemic rats remains unclear. In this study we investigated the effects of mTOR inhibition on lipopolysaccharide (LPS)-induced changes on expressions and/or activities of ribosomal protein S6 (rpS6), an mTOR substrate, nuclear factor-κB (NF-κB) p65, inhibitor κB (IκB)-α, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 with production of nitric oxide, peroxynitrite, prostacyclin, and tumor necrosis factor (TNF)-α and activity of myeloperoxidase (MPO), which results in hypotension and inflammation. Injection of LPS (10mg/kg, i.p.) to male Wistar rats decreased blood pressure and increased heart rate that were associated with elevated nitrotyrosine, 6-keto-PGF1α, and TNF-α levels and MPO activity, and increased expressions and/or activities of rpS6, NF-κB p65, iNOS, and COX-2 and decreased expression of IκB-α in renal, cardiac, and vascular tissues. LPS also increased serum and tissue nitrite levels. Rapamycin (1mg/kg, i.p.) given one h after injection of LPS reversed these effects of LPS. These data suggest that the activation of mTOR/IκB-α/NF-κB pathway associated with vasodilator and proinflammatory mediator formation contributes to LPS-induced hypotension and inflammation.


Assuntos
Hipotensão/induzido quimicamente , Hipotensão/patologia , Proteínas I-kappa B/metabolismo , Lipopolissacarídeos/farmacologia , Transdução de Sinais/efeitos dos fármacos , Serina-Treonina Quinases TOR/metabolismo , Fator de Transcrição RelA/metabolismo , 6-Cetoprostaglandina F1 alfa/metabolismo , Animais , Pressão Arterial/efeitos dos fármacos , Ciclo-Oxigenase 2/metabolismo , Epoprostenol/biossíntese , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Hipotensão/metabolismo , Hipotensão/fisiopatologia , Inflamação/induzido quimicamente , Inflamação/patologia , Masculino , Óxido Nítrico/biossíntese , Óxido Nítrico Sintase Tipo II/metabolismo , Peroxidase/metabolismo , Ácido Peroxinitroso/biossíntese , Ratos , Ratos Wistar , Proteína S6 Ribossômica/metabolismo , Fator de Necrose Tumoral alfa/biossíntese , Tirosina/análogos & derivados , Tirosina/metabolismo
4.
Pharmacology ; 78(3): 123-8, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17008773

RESUMO

This study was conducted to determine if mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase (ERK1/2) contribute to endotoxin-induced vascular hyporeactivity via nitric oxide (NO) and/or prostacyclin (PGI(2)) production in the rat isolated thoracic aorta. Incubation of endothelium-intact rings with endotoxin (100 microg/ml) for 4 h decreased the E(max) value and increased the EC(50) value of norepinephrine. The endotoxin-induced increase in the EC(50) value of norepinephrine was decreased by phenylene-1,3-bis[ethane-2-isothiourea] dihydrobromide (1,3-PBIT), a selective inducible NO synthase inhibitor, and U0126, a selective inhibitor of ERK1/2 phosphorylation by MAPK kinase. The endotoxin-induced decrease in the E(max) value of norepinephrine was reversed by 1,3-PBIT and further decreased by U0126. 1,3-PBIT and U0126 decreased the endotoxin-induced increase in the tissue nitrite and 6-keto-PGF(1)(alpha) levels. These data suggest that events related to the activation of ERK1/2 contribute to the endotoxin-induced hyporeactivity by increasing NO and PGI(2) production.


Assuntos
Aorta Torácica/efeitos dos fármacos , Endotoxinas/farmacologia , Epoprostenol/biossíntese , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Óxido Nítrico/biossíntese , Vasoconstrição/efeitos dos fármacos , Animais , Aorta Torácica/enzimologia , Aorta Torácica/metabolismo , Relação Dose-Resposta a Droga , Ativação Enzimática , Técnicas In Vitro , Masculino , Fosforilação , Ratos , Ratos Wistar , Vasoconstritores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA